Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Kither Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

Details:

Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.

Lead Product(s): KIT2014

Therapeutic Area: Genetic Disease Product Name: KIT2014

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Claris Ventures

Deal Size: $18.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing March 16, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY